Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director

Ocuphire Pharma, Inc. (OCUP) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/28/2019 GN Rexahn Announces Move to Nasdaq
05/13/2019 GN Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results
04/19/2019 GN Analysis: Positioning to Benefit within Nordic American Tankers, Safeguard Scientifics, Permian Basin Royalty Trust, Coda Octopus Group, Rexahn Pharmaceuticals, and Diversified Restaurant ?? Research Highlights Growth, Revenue, and Consolidated Results
04/16/2019 GN Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
04/12/2019 GN Rexahn Effects 1-for-12 Reverse Stock Split
04/10/2019 GN Rexahn Announces Reverse Stock Split
03/27/2019 GN Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting
03/08/2019 GN Rexahn Pharmaceuticals Reports 2018 Financial Results
03/01/2019 GN Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
02/06/2019 GN Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium
02/04/2019 GN Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types
01/24/2019 GN Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
01/22/2019 GN Rexahn Announces Proposed Public Offering of Common Stock and Warrants
01/22/2019 GN Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
01/14/2019 GN Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium
12/11/2018 GN Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
12/06/2018 GN Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline
11/05/2018 GN Rexahn Reports Third Quarter 2018 Financial Results
10/17/2018 GN Rexahn Announces $7.5 Million Registered Direct Offering
08/21/2018 GN Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
08/06/2018 GN Rexahn Reports Second Quarter 2018 Financial Results
06/14/2018 GN Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018
05/03/2018 GN Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP — Research Highlights Growth, Revenue, and Consolidated Results
05/03/2018 GN Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP — Research Highlights Growth, Revenue, and Consolidated Results
04/26/2018 GN Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
03/22/2018 GN Research Report Identifies Westinghouse Air Brake Technologies, National Western Life Group, Impinj, Ingles Markets, RCI Hospitality, and Rexahn Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
03/13/2018 GN Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
03/12/2018 GN Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results
02/08/2018 GN Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma
01/29/2018 GN Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
01/22/2018 GN Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
01/18/2018 GN Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
12/11/2017 GN Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium
11/09/2017 GN Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy